It has long been known that diabetes is a disease that requires an individualized treatment protocol in order to manage the condition. The Insuvet range includes Insuvet Lente with medium duration and onset, Insuvet Protamine Zinc with longer duration and onset (an ideal choice for some cat owners who may find twice daily injections problematic), and Insuvet Neutral, which should be kept in every practice to manage acute diabetic ketoacidosis.
Susan Mitchell, Insuvet Product Manager said: "A flexible approach allows patients to be managed more effectively; both from the point of view of the patient's needs but also those of the owner too. People have increasingly busy schedules and providing a solution that fits with lifestyle and helps deal with any diabetic crises that do occasionally occur, will ensure successful long term management of the condition."
The team at Pfizer has been busy undergoing intensive technical training and is equipped to provide assistance with diabetic cases. Regional support is now available in the shape of dedicated Area Veterinary Managers who can provide practices with comprehensive support, backed up with a national technical support helpline.
The company has available a wide range of support materials that include stabilisation protocols, blood glucose monitoring charts and communication aids that explain the condition to the client, with the promise of an even more comprehensive range of exciting and innovative aids to come in the next few months.
For further information on the Insuvet range vets and nurses should contact their Pfizer Business Account Manager. For advice on individual cases or any other technical questions about diabetes call the Technical Support Line on 0845 3008034.
According to statistics from the RCVS, almost 40% of veterinary surgeons that have registered in the UK since 2005 qualified from veterinary schools elsewhere in the EU.
Of course, it's not just in general practice that veterinary surgeons and veterinary nurses from other EU member states make such an important contribution. They work across all areas of veterinary science, including the fields of animal health and welfare, animal disease surveillance, scientific research and education, wildlife conservation, and public health and food safety.
Figures from the Veterinary Public Health Association (VPHA) estimate that over 90% of vets in meat hygiene services are non-British EU citizens.
To highlight the impact of Brexit on the veterinary profession, the BVA has written to the Secretary of State, Liz Truss MP, and to Ministers in Scotland, Wales and Northern Ireland, requesting an early statement to the effect that non-British EU vets and vet nurses who are currently living, studying or working in the UK will continue to be able to do so in future.
BVA is also seeking reassurance for UK veterinary professionals working and studying in other EU member states.
BVA President Sean Wensley said: "It is not yet possible to comment on the reality of ‘Brexit’ since much will depend on forthcoming negotiations and the decisions that will be taken by the Government regarding, for example, whether or not to maintain existing EU legislation and rules. However, we recognise that these unanswered questions are having a profound impact on many of our members – particularly members who are non-British EU citizens, or have family members who are, and members who work alongside colleagues from other European Member States."
In the letters, Mr Wensley wrote: "I am sure there are many significant issues that your Department needs to consider [and] given the profound personal impact that the uncertainty caused by the referendum outcome is having on some of our members, we wanted to contact you at the earliest opportunity. In the forthcoming negotiations about the future relationship between the UK and the EU, we strongly urge you to make the case for all EU citizens and EU-qualified veterinary surgeons and nurses to have ongoing rights to live, work and study in the UK."
In the letter to the Northern Ireland (NI) Minister of Agriculture, Environment and Rural Affairs Michelle McIlveen MLA, the BVA President and BVA NI Branch President Seamus O’Kane highlighted NI’s land border with EU member state the Republic of Ireland and called for the maintenance of the Common Travel Area to facilitate movement in an all-island context for both work and study purposes.
VPHA President Lewis Grant said: "Due to the particular focus on public health in many European veterinary degree courses, EU vets make an enormous contribution to both public health and animal health and welfare in the UK - often behind closed doors, monitoring and protecting public health in Approved Premises as well as welfare at slaughter to ensure slaughterhouses meet the standards that are required by law and expected by the public. Without their input and expertise, it would be difficult to ensure that Statutory requirements within the food industry are complied with."
You can complete the PDSA Animal Wellbeing (PAW) survey at: yougov.com/pdsa.
Rebecca Ashman, PDSA Policy and Campaigns Manager, said: "Since 2011, our PAW Report has provided valuable insight into pet health and wellbeing across the UK.
"It delivers a vital evidence base for education programmes, campaigns and collaborative work in the veterinary and welfare sectors. It also enables us to monitor the impact of welfare initiatives on pet wellbeing issues which are of most concern to the veterinary profession.
"The survey only takes 15 minutes to complete, and by taking part, you’ll be helping us to capture an accurate picture of the welfare issues that are of the biggest concern for the veterinary profession. You can also be entered into a prize draw to win a GoPro HERO5 Session Action Camera."
For more information and to download the 2017 PAW Report, visit pdsa.org.uk/pawreport.
The new bill - Animal Welfare (Sentencing and Recognition of Sentience) - would increase the maximum prison sentence for animal cruelty tenfold, from six months to five years, in England and Wales.
The draft bill also sets out that the government "must have regard to the welfare needs of animals as sentient beings in formulating and implementing government policy".
Subject to consultation on the draft bill, the government says it will legislate to deliver both aims.
In fact, the draft bill goes further than Article 13 as it applies to all areas of government policy, rather than specified areas of policy. If passed, the law would apply to the whole of the UK.
Environment Secretary Michael Gove said: "Animals are sentient beings who feel pain and suffering, so we are writing that principle into law and ensuring that we protect their welfare. Our plans will also increase sentences for those who commit the most heinous acts of animal cruelty to five years in jail. We are a nation of animal lovers so we will make Brexit work not just for citizens but for the animals we love and cherish too."
BVA President John Fishwick said: "Vets have been clear in our calls that the duty on the state to have due regard for animal welfare - as captured in Article 13 of the EU Lisbon Treaty - must be enshrined in UK law. This Bill captures the substantive obligation that Article 13 currently puts on the national government to consider animal welfare, as well as explicitly recognising animals as sentient beings."
"Today’s draft Bill lays out in black and white the Government making good on its promises, to ensure the UK remains a global leader in animal welfare post-Brexit."
In an internal study, Royal Canin found that Pill Assist Cat achieved over 91% pill acceptance.
Pill Assist Cat is enriched with vitamins and prebiotics to support a cat’s recovery, and each treat contains only three calories.
Elisabete Capitao, Royal Canin Veterinary Marketing Manager said: "We know that getting cats to take pills can be quite a challenge even for the most experienced pet owners! A quarter of owners leave the veterinary clinic with oral medication for their cat, but 40% find giving pills to their cat complicated. Pill Assist Cat makes giving cats medication easy and takes the stress out of pill time."
Royal Canin says Pill Assist Cat is suitable for most types of medication, from worming tablets to medication for an illness.
Eurovet Animal Health has launched Cardisure, a new look pimobendan which the company claims will help deliver more precise dosing in the treatment of cardiac disease.
Dogs have the widest range in bodyweight of any species, and it's long been a problem accommodating the wide variation in dosage requirements that this leads to. Having to give too many tablets in a day or the need to split small tablets can be very discouraging to owners and may lead to poorer rates of compliance.
Cardisure is available in 1.25 mg, 2.5 mg, 5 mg tablets and a 10 mg tablet size. Eurovet says the tablets are easily divisible and palatable, making it easier all round for pet owners to administer the right dose of medication to their pet.
Eurovet says the benefits of treating heart disease with pimobendan are well-established and that Cardisure gives clinicians a few more client-friendly options when it comes to treating heart disease, as well as being available in smart and professional blister packs for easy dispensing.
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Reference
In a statement given to the Veterinary Record earlier this year, the College said:
"In 2017, our commitment to equality for our LGBTQ+ employees, members of the professions and other stakeholders, was cemented when we became a Stonewall Diversity Champion, with the aim of ensuring that all people in the community are accepted, without exception, within the veterinary professions.
In subsequent years this commitment has been demonstrated by the establishment of our Diversity & Inclusion Group, for which LGBTQ+ representation is a key component and has been incorporated into both our internal and external diversity and inclusion strategies.
Focusing on our internal diversity and inclusion strategy, the insight from Stonewall and our internal LGBTQ+ group, has aimed to make the RCVS a safe space for people from the LGBTQ+ community by creating a fully inclusive workplace.
These insights have also fed into the profession-facing work of the Diversity & Inclusion Group and its strategy.
After six years as a Stonewall Diversity Champion, we have decided this year not to renew our contract with the organisation, on the basis that we feel we no longer need to work with an external organisation to continue to deliver on our commitment to equality, diversity and inclusion.
The RCVS will continue to demonstrate allyship and be a safe space for all groups within the LGBTQ+ community, as demonstrated by the fact we are creating a staff network representing RCVS colleagues from marginalised communities.
We may in future decide to work with another accredited organisation, but until the staff network is in place, no decisions have been made. For example, we have recently brought in a staff policy regarding how best to support RCVS employees who are going through the process of gender reassignment, reiterating the current legal position, how to report experiencing or witnessing transphobic discrimination, as well as advice for colleagues supporting those undergoing gender reassignment and those who have family members going through the process. We are grateful for Stonewall for working with us over the past six years and helping us, through its Workplace Equality Index, to finesse our policies and procedures in relation to LGBTQ+ rights and issues and drive forward our agenda to be a diverse and inclusive workplace and regulator."
Reporter Andy Davies spoke to Charlotte Debbaut MRCVS, a veterinary surgeon from Belgium working at the Tindale Veterinary Practice in Gloucestershire, where there are 13 vets with eight different nationalities. He also interviewed Matthew Pugh MRCVS and Ovidiu Oltean MRCVS from Belmont Veterinary Centre, a mixed practice in Hereford which employs five foreign nationals out of a team of 13 veterinary surgeons.
Finally, he talked to John Blackwell MRCVS at Brownlow Veterinary Group in Shropshire, where Brexit had already caused a Croatian member of his team to refuse a permanent position and return to Ireland.
Congratulations to the RCVS and BVA press offices, who will have been hard at work behind the scenes.
See: https://www.channel4.com/news/brexit-affecting-vet-recruitment
The new product is being sold through e-retailers including Pet Drugs Online, Animed and Pets at Home.
Frontpro is claimed to kill fleas within 8 hours and protect dogs from fleas and ticks for one month.
It is suitable for all breeds aged eight weeks or older (weighing two kilograms or more) and can be given with or without food.
A company spokesperson said: "Boehringer Ingelheim is committed to expanding access to high-quality parasite prevention for dogs, which is why we’re proud to introduce an effective new option.
"Frontpro chewable tablets provide effective protection from fleas and ticks, while complementing the regular care and advice pet owners receive from their veterinarians."
www.uk.frontline.com
MSD Animal Health has launched Bovilis IBR Marker Inac, an inactivated marker vaccine for use in the control of Infectious Bovine Rhinotracheitis (IBR).
The company says the new product complements Bovilis IBR Marker Live and creates a range now offering greater simplicity and additional flexibility for veterinary surgeons seeking optimum control protocols for their clients' herds.
MSD Animal Health ruminant veterinary adviser Drew McGurren MRCVS said: "Farmer compliance is an important part of any successful vaccination programme. With this extended Bovilis IBR Marker programme, farmers can now start IBR vaccination of their cattle from three months of age with a single shot primary course of Bovilis IBR Marker Live, easily followed by boosters every six months using a single dose of either Bovilis IBR Marker Live or Bovilis IBR Marker Inac. Both primary course and boosters can be administered by the same intramuscular route.
"Alternatively, Bovilis IBR Marker Inac can be administered to cattle from three months of age as a primary course of two injections four weeks apart. The programme then follows a six monthly single dose booster regime.
"The availability of Bovilis IBR Marker Inac provides a simple control option in defined farm situations, not least where an alternative to the live vaccine is preferred or required. Overall, we see this development adding convenience, ease of use and flexibility for veterinary surgeons as they work with their clients to control a significant disease threat in dairy and beef cattle in the UK."
Bovilis IBR Marker Inac is a prescription-only medicine (POM-V). The product is available from wholesalers now in 10 and 50 dose vials. For further information, contact the MSD Animal Health Veterinary Support Group on 01908 685685.
Norbrook has announced the launch of Marbodex Aural, the most recent addition to its Otitis Management System for dogs.
Norbrook says the ingredients in Marbodex Aural (marbofloxacin, clotrimazole, dexamethasone) are proven to relieve pain and inflammation quickly, deal with key bacterial and fungal infections effectively and thereby improve pet comfort.
The company says the inclusion of marbofloxacin makes Marbodex Aural an ideal first choice for cases of otitis externa that are:
Marbodex Aural also contains clotrimazole, a broad spectrum antifungal effective against otitis caused by Malassezia pachydermatis, and dexamethasone, a fast acting steroid whose absorption is not increased in inflamed ears.
Marbodex Aural is applied once a day and has two soft nozzles to reduce pain on application and prevent cross-contamination during treatment. It can be used for extended treatment periods of seven to fourteen days when treating persistent infections.
Marbodex Aural is available in all veterinary wholesalers now. For more information about Marbodex and to take advantage of the launch offers, contact your Norbrook Territory Manager or call 01536 741147 for more information.
Reference:
According to the AHT, there is undisputed evidence that owners, riders and trainers have a poor ability to recognise signs of pain seen when horses are ridden. As a result, problems are labelled as training-related, rider-related, behavioural, or deemed 'normal' for that horse because 'that’s how he’s always gone'.
This, says the AHT, means pain-related problems are often disregarded, the horse continues in work, and the problem gets progressively worse.
Dr Sue Dyson, Head of Clinical Orthopaedics at the AHT, believes it may be easier to educate riders and trainers to recognise changes in facial expression and behaviour rather than lameness. So she and her team set out to develop and test an ethogram to describe facial expressions in ridden horses and to determine whether individuals could interpret and correctly apply the ethogram consistently.
At this stage in the project, they concluded that their ethogram could reliably be used to describe facial expressions of ridden horses by people from different professional backgrounds (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(16)30184-8/fulltext).
In the next stage of the project, Sue and her team sought to demonstrate that the ethogram could be used to identify lameness.
The ethogram was applied blindly by a trained analyst to photographs (n=519) of the head and neck of lame (n=76) and non-lame (n=25) horses acquired during ridden schooling-type work at both trot and canter. These included images of seven lame horses acquired before (n=30 photographs) and after diagnostic analgesia had abolished lameness (n=22 photographs).
A pain score (0-3; 0=normal, 1-3=abnormal) was applied to each feature in the ethogram, based on published descriptions of pain in horses.
A total of 27,407 facial markers were recorded, with those giving the greatest significant difference between lame and sound horses including ears back, eyes partially or fully closed, an open mouth with exposed teeth and being severely above the bit.
Pain scores were higher for lame horses than non-lame horses (p<0.001). Total pain score (p<0.05), total head position score (p<0.01), and total ear score (p<0.01) were reduced in lame horses after abolition of lameness.
Severely ‘above the bit’, twisting the head, asymmetrical position of the bit, ear position (both ears backwards, one ear backwards and one to the side, one ear backwards and one ear forwards) and eye features (exposure of the sclera, the eye partially or completely closed, muscle tension caudal to the eye, an intense stare) were the best indicators of pain.
The researchers concluded that application of the ethogram and pain score could differentiate between lame and non-lame horses. Assessment of facial expression could potentially improve recognition of pain-related gait abnormalities in ridden horses (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(17)30019-9/fulltext)
Sue and her team are now working on the development of a whole horse ethogram and its application to non-lame and lame horses, to help to differentiate between manifestations of conflict behaviour, in response to the demands of the rider, and pain. They are also working towards the development of a practical tool for recognising facial expressions, similar to that of a body condition score chart, which they say could dramatically improve the health and welfare of all horses.
Photo: Signs of pain include ears back (pain score of 3), intense stare, muscle tension and mouth. Courtesy Dr Sue Tyson.
Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.
Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.
Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.
For more information, contact your Boehringer Ingelheim representative.
The British Small Animal Veterinary Association (BSAVA) has announced that it is opening its membership to RCVS registered veterinary nurses for the first time.
BSAVA has always been keenly involved with veterinary nurse issues and has representation on the RCVS nurse Awarding Body Board and observers on VN Council. Membership Development Committee Chair Patricia Colville said: "The association strongly believes that are nurses are integral to the care the profession offers to patients, and we have always taken advice from our members on ways we can support nurses on the many issues that they have been faced with over the last number of years, from the change in nurse training to compulsory CPD and the future change to self-regulation. Now it is time to formally recognise the services we offer to VNs and bring them into a package of benefits that they can collect as a member of the Association".
Patricia added: "There have been many changes over the last 50 years, during which nurse training has developed in its own right. The depth and breadth of knowledge that nurses have, and the amount of work that they have to do to gain the VN qualification is vast and it is a great credit to the veterinary world that this level of dedication has developed. It is fantastic to see the amount of CPD on offer now and the enthusiasm and dedication that nurses show in continuing to develop their skills, which has contributed to the betterment of practice life and animal welfare".
Membership for VNs is being launched at the first year introductory price of £66 in 2011, rising to £100 per annum in 2012.
Practices interested in how BSAVA membership can support their nursing staff, and veterinary nurses interested in membership should register at http://www.bsava.com/, email administration@bsava.com or call 01452 726700.
The webinar, which takes place on Thursday 30th June at 7.30pm, is being presented by Debbie Boone, billed as one of America’s most prominent and experienced veterinary communications consultants.
Gerrard Harkins, Premier Vet Alliance’s Commercial Director said: “Many people struggle with managing challenging behaviour and confrontation in the workplace and Debbie will be focusing on providing delegates with pragmatic advice and skills to put into practice.
"She is one of the veterinary industry’s most prominent and successful communicators so we’re extremely fortunate to be able to access her advice.
“We’re also looking forward to gaining a US perspective on this important subject.”
To register for the webinar, visit: https://tinyl.io/5aIk
Zoetis, formerly Pfizer Animal Health has launched Ovatec Plus, which it claims will make equine faecal collection and in-practice worm count testing quicker and easier.
Ovatec Plus is designed to facilitate the in-house detection of worm burdens by enabling the coproscopic examination of parasite eggs, larvae and cysts. Zoetis says the built-in sample collection scoop allows for hands-off, quick, clean sample collection and controlled sample size, while the built-in cap, which can be written on for easy identification, snaps shut to seals the contents safely for contamination-free transport.
The system is based on zinc sulphate flotation technology, with a flotation time of ten minutes to provide rapid analysis. The Ova-Spin feature will break up difficult samples. The positive-locking filter chamber prevents any spill of test samples and reduces operator exposure to potential hazards. The overflow reservoir prevents overfills leaking onto the lab bench.
Zoetis says the high sensitivity and excellent specificity of Ovatec Plus enable informed treatment decisions to be made. A study has shown that samples proving negative with Ovatec Plus provide 95% certainty that the sample is <150epg and 100% certainty that the sample is <250epg, which means treatment may not be necessary1. Samples that prove positive, with one or more eggs seen, can be verified using a quantitative technique if needed, alternatively treatment may be indicated.
Ben Lacey, equine business unit manager at Zoetis, said: "Ovatec Plus is an excellent addition to our equine worm control portfolio. It's ideal for use in many test situations, giving a quick, easy and convenient solution."
To find out more, speak to your Zoetis Account Manager, call 0845 300 8034 or email CustomerSupportUK@zoetis.com.
Dr Power faced a number of charges relating to alleged clinical and communications failings surrounding surgery carried out on two separate dogs on two separate occasions.
The first concerned laryngeal tieback surgery carried out on Harvey, a Tibetan Terrier in March 2018, and the second concerned oesophageal surgery carried out on a boxer dog, Boss, in October 2018.
The College withdrew a number of the charges at the start of the hearing, and more later after hearing from witnesses.
Of the remainder, Dr Power admitted that she had not undertaken pre-operative radiographs before proceeding with the laryngeal surgery, had failed to perform the surgery appropriately (she dissected excessive tissue and had inappropriately placed sutures), and had undertaken the surgery when it was outside her area of competence.
In relation to the oesophageal surgery, Dr Power admitted failing to provide a referral report and/or clinical records to the veterinary practice he was referred from, despite requests from the practice.
The Committee found that the majority of the charges which had not been withdrawn or admitted by Dr Power, not proven.
However, the Committee found that in addition to the admitted charges, Dr Power had subjected the dog undergoing oesophageal surgery to an excessive 9.5 hours of anaesthesia.
The Committee then went on to consider whether the proven charges amounted to serious professional conduct.
Counsel for the College submitted that Dr Power’s conduct breached the part of the Code of Professional Conduct relating to veterinary surgeons keeping within their area of competence and referring responsibly; and providing veterinary care that is appropriate and adequate.
In terms of aggravating factors, the College submitted that there was both actual injury to the animal, as well as actions that posed a risk of injury, that Dr Power financially benefitted from the alleged misconduct as she was paid to perform a procedure outside her competence, and that she occupied a position of increased trust and responsibility as she advertised herself as a practitioner who accepted referrals and was competent to perform soft tissue surgery.
Dr Power’s counsel submitted that the charges that had been found proven amounted to clinical and administrative failings and that this was not a case of a veterinary surgeon deliberately or recklessly acting outside of their capabilities, but rather a case where a diligent and responsible veterinary surgeon had fallen short in discrete areas of her clinical practice and had reasonably believed at the time that she was competent to perform the surgery.
The Committee found that although the conduct within the proven charges fell short of what would be reasonably expected of a veterinary surgeon, it did not fall so far short that her conduct constituted serious professional misconduct.
Paul Morris, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee understood that it had a responsibility to consider the wider public interest, taking into account the view of a reasonable member of the public in possession of all the relevant facts and information.
“The Committee considered that such a member of the public would understand that veterinary surgery is a challenging profession. It was of the view that such a member of the public would not expect perfection, but understand that any professional practitioner may make mistakes in the course of their practice.
“It is the judgement of this Committee that the respondent’s conduct does not constitute disgraceful conduct in a professional respect.”
The full findings of the Disciplinary Committee can be found at www.rcvs.org.uk/disciplinary
The BVA officer team consists of BVA President, Senior Vice President (SVP) and Junior Vice President (JVP).
BVA Officers collectively, and working closely with the Chief Executive and his team, provide leadership to BVA to help ensure the Association fulfils its mission to be the leading body representing, supporting and championing BVA members and the whole UK veterinary profession.
The BVA says it's looking for applications for the next JVP (2018/2019), becoming BVA President in 2019/20, from BVA members:
Nominations for the next JVP are confidential and will be assessed by the BVA Electoral College, which assesses nominations and formally selects members for election to BVA officer status.
Each officer role (JVP, President, SVP) is for one-year term from BVA’s Annual General Meeting (AGM) in September to the AGM the following September.
Candidates for JVP and President must be elected by the membership at the AGM to serve the coming year. The total commitment is therefore three years as a BVA officer, plus a further three years serving as a past president on BVA Council (four meetings per year).
BVA President John Fishwick said: "As a BVA officer, it is a huge honour to represent the UK’s veterinary profession however it is not simply an ‘honorary role’, particularly during this time of professional, social and political upheaval when BVA is supporting and championing the vital role vets play more than ever before.
"I have been a BVA officer for 15 months now and it is a privilege to be so involved in a profession that is pivotal to animal health and welfare, and public health too. Part of the role is representing the views of our profession clearly and concisely to policymakers, politicians and the media and, although this may seem daunting, you have the full support of the BVA team and are given invaluable training. I would encourage anyone with a passion to promote the value of the veterinary profession, and who is seeking a fulfilling role, to apply to help ensure BVA continues to be a strong voice for our profession."
BVA members who are interested in applying for, or nominating a fellow BVA member with their consent to become part of the BVA officer team, can apply before 9am on 15 January 2018 at www.bva.co.uk/elections
BEVA says it was aware, from both younger members and their employers, that there were some equine fields, for which the association had no courses, where newer graduates were lacking in clinical skills.
The new Equine Practice Fundamentals Programme comprises 10 individual CPD courses with a mix of lectures and hands-on practicals. BEVA says it builds on the broad training delivered by the universities to specifically provide the pragmatic knowledge and hands-on clinical skills needed by those in the early stages of an equine veterinary career.
The content was designed on the back of consultation with over 60 senior practitioners from across BEVA’s membership.
The average senior practitioner rated the likelihood that they would encourage recent graduates to attend the programme as 9/10 and BEVA says feedback on the initial course proposal was highly encouraging.
The courses cover:
David Mountford, Chief Executive of BEVA, said: "Because BEVA doesn’t seek to make a profit on its CPD we can deliver an outstanding programme that is both highly regarded and affordable. We anticipate that the series will become essential CPD for those looking to establish themselves in equine practice, for practices looking to support the development of new staff, and for employers looking to differentiate between candidates."
The first five courses will be running during 2018 and again in 2019 together with the remaining five. The full series of ten courses can be booked at a discounted rate. Alternatively, each course can be booked individually.
For further information visit https://www.beva.org.uk/Home/Education/CPD/The-Fundamentals-of-Equine-Practice
Assets coming up for sale via private treaty and online auction include:
For a full list of assets, visit: https://www.bidspotter.co.uk/en-gb/auction-catalogues/timed/gordonbrothers/catalogue-id-gordon10067
Gordon Brothers Valuations & Industrial Director, Simon Bamford said: “Gordon Brothers is pleased to be assisting the Trustees of the Animal Health Trust with the orderly closure of the 100 acre Newmarket facilities, including the sale of the large quantity of associated assets. We are expecting significant interest in the varied array of assets”
The online auction will close at 3.00pm on the 1st October 2020. Viewing is strictly by appointment only on Monday 28th and Tuesday 29th September 2020 from 9.00am to 4.00pm at AHT, Lanwades Park, Kentford, Newmarket, CB8 7UU.
For further enquires on the sale or to view by appointment please contact, Josh Chivers jchivers@gordonbrothers.com
A second sale comprising of a large quantity of laboratory and research equipment and agricultural plant and machinery will take place in October 2020 with further details to be released.
The RCVS has announced that it has accepted the resignation of council member Bob Partridge.
Bob, who had been an elected member of the RCVS Council since July 2006, tendered his resignation for personal reasons.
Peter Robinson will take up the vacated Council position, as he came next in the ballot in the 2013 election.
Dilaterol is an oral syrup containing 25 mgs/ml clenbuterol hydrochloride, indicated to treat respiratory disease in horses. It causes intense bronchodilation, inhibits histamine release and increases ciliary mucous clearance. It can be used as a frontline or adjuvant therapy.
Dilaterol is administered via food and comes in a 355 ml bottle with a pump dispenser for easy and accurate dosing.
Emma Jennings, Equine Brand Manager at Dechra said: “We are very pleased to have added Dilaterol to our comprehensive range of equine therapies as it is an established and effective treatment for bronchial conditions.
"It is particularly useful in cases of respiratory allergy, bronchospasm and equine asthma and is already regarded as a valuable tool for veterinary professionals."
Dilaterol will be available to order through wholesalers. For more information, visit www.dechra.co.uk.
The Easy to Give Awards are given to pharmaceutical companies that have made it easier to give medication to cats:
Dechra for Felimazole coated tablets for cats
Zoetis for Stronghold Plus spot-on solution for cats
Zoetis for VibraVet Paste
Bayer for Seresto flea and tick collar for cats
The Cat Friendly Awards recognise products which have made a difference to cat wellbeing:
ProtectaPet for cat fencing solutions
Coastline Global for Kit4Cat Cat Urine Sample Collection Sand
Sure Petcare for its SureFlap Microchip Pet Door Connect with Hub
The Distance Education Awards recognise the best students on the International Society of Feline Medicine’s Vet Nursing courses
Sarah Hayward and Rachael Hodgeson for best results achieved in the Certificate in Feline Nursing
Margaret Hodgeson for the best result received in the Diploma in Feline Nursing
In addition, International Cat Care made a special award in 2018 for products and ideas which have made major contributions to the ability to help cats in the field of Trap, Neuter, Return (TNR). The Innovation in Humane Cat Population Management Award was given to MDC Exports for its traps, restrainers and transfer baskets.
Lastly, the winner of the 2018 iCatCare Photography Competition winner, awarded to the overall winner of the charity’s ‘Kittenhood’ photo competition, was Lindsey Chadwick.
Photo: Liz Rawlings and Craig Sankey from Dechra with their Easy to Give award for Felimazole
Alstoe Animal Health has announced that Vetergesic (buprenorphine), the UK's most commonly used injectable opiate for small animal use, is now registered for use in horses.
Developed and manufactured in the UK, Alstoe took over marketing Vetergesic 11 years ago. Two years ago the company introduced the Multi-Dose Pack, which it says allows veterinary surgeons to manage the larger liquid volumes required in horses more easily.
Alstoe says Vetergesic potentiates sedative drugs for standing sedation or routine premedication and provides profound centrally acting analgesic effects for up to nine hours. In routine procedures, this allows good recoveries and a rapid return to normal behaviour patterns.
Alstoe also says that in a thermal anti-nociceptive study carried out at Bristol University, Vetergesic showed significantly better analgesic effects than butorphanol. Field studies carried out in the UK also confirmed that when combined with a sedative, Vetergesic can provide up to 60 minutes of operating time, with smooth and quick recoveries.
John Nellis of Alstoe said: "We have invested heavily in this product and are confident that the rewards enjoyed by small animal vets will also be appreciated by their equine colleagues. We call Vetergesic 'the thoroughbred of pain management'."
Vetergesic Multidose is available for dogs, cats and horses in a 10 ml vial.
Alstoe offers an hour long explanatory seminar, which can be delivered directly to practice members. An 8 page brochure and 'pocket-sized' dose chart are also available. Further details from Alstoe on: 01347 878606 or email: info@alstoe.co.uk .